Connor, Clark & Lunn Investment Management (CC&L)’s Minerva Neurosciences NERV Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio NERV Stock Details NERV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-17,970	Closed	-$250K	–	1161
2021 Q3	$250K	Buy	17,970 +4,486	+33%	+$67.5K	﹤0.01%	910
2021 Q2	$250K	Buy	13,484 +1,261	+10%	+$27.1K	﹤0.01%	879
2021 Q1	$286K	Buy	12,223 +3,770	+45%	+$94.2K	﹤0.01%	873
2020 Q4	$158K	Buy	+8,453	New	+$213K	﹤0.01%	841
2020 Q2	–	Sell	-12,107	Closed	-$583K	–	1130
2020 Q1	$583K	Sell	12,107 -5,190	-30%	-$313K	0.01%	659
2019 Q4	$984K	Sell	17,297 -619	-3%	-$27.3K	0.01%	547
2019 Q3	$1.11M	Buy	17,916 +7,607	+74%	+$431K	0.01%	524
2019 Q2	$464K	Buy	+10,309	New	+$516K	﹤0.01%	736

Other funds holding NERV

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

SEI Investments Oaks, Pennsylvania $108B AUM 26.14% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s NERV Position: Q4 2021 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Minerva Neurosciences (NERV) in Q4 2021, closing a stake of 17,970 shares — an estimated $250K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in NERV in Q2 2019 and held it in 8 quarters. The position peaked at $1.11M in Q3 2019. 35 funds tracked by Wall St. Rank hold NERV as of Q4 2021.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Minerva Neurosciences position as of Q4 2021 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 17,970 Minerva Neurosciences shares in Q4 2021, an estimated $250K.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Minerva Neurosciences in Q2 2019 and held it in 8 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s Minerva Neurosciences position peaked at $1.11M in Q3 2019.
35 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q4 2021.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q4 2021, filed 10 Feb 2022.